Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGS01
- Development stage
- Preclinical
- Lead developer
- Ignis Therapeutics
- Modality
- Small Molecules
01
Overview
IGS01 is an investigational drug candidate currently in the preclinical stage of development by Ignis Therapeutics. It is being developed for the treatment of Parkinson's Disease Psychosis (PDP) and chronic pain. Ignis Therapeutics, a CNS-focused biotechnology company established as a joint venture between SK Biopharmaceuticals and 6 Dimensions Capital, has not publicly disclosed the specific molecular target or mechanism of action for IGS01. The program is part of the company's internal research and development pipeline, which aims to address unmet needs in neuropsychiatric and neurological disorders through the development of innovative small molecule therapeutics.
02
Targets
CHRM4 (M4)
Beyond the preview
Go deeper on IGS01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGS01.